ClinicalTrials.gg
CompletedNCT06193200NEATUpdated Apr 30, 2026Results posted

Evaluate the Neurological Effects of EryDex on Subjects With A-T

A Phase 3 interventional study of Dexamethasone sodium phosphate and Placebo in Ataxia Telangiectasia, sponsored by Quince Therapeutics S.p.A.. Completed at 19 sites in 9 countries. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2026-04-30.

Sponsored by Quince Therapeutics S.p.A. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
6 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Ataxia Telangiectasia with a site in United States — 2 open to participants now, 4 under way, 1 of them phase 3. Ataxia Telangiectasia · United States.

Enrollment
Largest of 13
105 · median 20
Started
2024
with 1 other
Phase 3
4 of 16
none open now
Registered
13th of 16
by date
Lead sponsor
4 of 16
Quince Therapeutics S.p.A.

Among the 16 studies in Ataxia Telangiectasia with a site in United States, this one has the largest enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2024, is one of 4 in phase 3, and was the 13th registered.

Ataxia Telangiectasia

42 studies on the registry are indexed under Ataxia Telangiectasia; 7 are open to participants now.

Browse Ataxia Telangiectasia studies →

Open to participants now

2 of the 16 studies in Ataxia Telangiectasia with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 5 Ataxia Telangiectasia studies recruiting now, 3 set no upper age limit and 2 stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 6 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Ataxia Telangiectasia with a site in United States, or all of them as a file.
02

Study summary

This is an international, multi-center, randomized, prospective, double-blind, placebo-controlled, Phase 3 study, designed to assess the effect of EryDex (dexamethasone sodium phosphate [DSP] in autologous erythrocytes), administered by intravenous (IV) infusion once every 28 days, on neurological symptoms of patients with Ataxia Telangiectasia (A-T).

Read the detailed description

The EryDex System (EDS) is a combination product that is used to load dexamethasone sodium phosphate (DSP) into autologous erythrocytes (EryDex) which is infused into the patient.

In the placebo arm, the subjects will receive autologous erythrocytes prepared with the EDS process using a placebo solution.

Upon completion of all screening assessments for eligibility, subjects meeting all selection criteria at baseline will be randomized in a 1:1 fashion to EryDex or placebo. Approximately 86 subjects 6- to 9-years-old, approximately 43 per group, will be randomized. Approximately 20 subjects 10 years of age and above, 10 per treatment group, may also be enrolled.

03

Conditions studied

  • Ataxia Telangiectasia

Browse trials for

Keywords

  • Ataxia Telangiectasia
  • A-T
  • Louis-Bar syndrome
  • Cerebello-oculocutaneous telangiectasia
04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of A-T
  • In autonomous gait or is helped by periodic use of a support
  • Genetic confirmation of A-T
  • Body weight ≥15 kg

Exclusion criteria

Exclusion Criteria:

  • Participation in another clinical study
  • Immune impairment
  • History of severe impairment of the immunological system
  • Current neoplastic disease or previous neoplastic disease not in remission for at least 2 years
  • Severe or unstable pulmonary disease
  • Uncontrolled diabetes
  • Current chronic or acute significant renal and/or hepatic impairment
  • Any previous oral or parenteral use within 6 weeks before Baseline. Treatment with inhaled or intranasal steroids for asthma or allergies, as well as use of topical steroids will be permitted
  • A disability that may prevent the subject from completing all study requirements
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
105 participants (actual)

Study arms

  • Experimental
    Dexamethasone sodium phosphate

    IV infusion of dexamethasone sodium phosphate (DSP) encapsulated in autologous erythrocytes using the EryDex System (EDS)

    Drug: Dexamethasone sodium phosphate

  • Placebo comparator
    Placebo

    IV infusion of placebo encapsulated in autologous erythrocytes using the EryDex System (EDS)

    Other: Placebo

Interventions

  • Dexamethasone sodium phosphate encapsulated in autologous erythrocytes and administered via IV infusion

    Also known as: DSP

  • OtherPlacebo

    Placebo encapsulated in autologous erythrocytes and administered via IV infusion

06

What researchers measure

Primary outcomes

  1. Rescored Modified International Cooperative Ataxia Rating Scale (RmICARS)

    Change of the RmICARS from baseline to Visit 9 compared to placebo (6 to 9 years old). RmICARS (International Cooperative Ataxia Rating Scale): Score (range 0-29); higher score indicates worse disease.

    Time frame: Baseline to Visit 9 (approximately 6 months)

Secondary outcomes

  1. Clinical Global Impression of Severity (CGI-S)

    CGI-S (Clinical Global Impression of Severity): 7-point scale; higher score indicates worse disease. 1 = Normal, not at all ill; 7 = Among the most extremely ill. Percentage of participants improving in CGI-S from baseline to Visit 9.

    Time frame: Baseline to Visit 9 (approximately 6 months)

  2. Clinical Global Impression of Change (CGI-C)

    CGI-C (Clinical Global Impression of Change): 7-point scale; higher score indicates worsening of disease. 1 = Very much improved; 4 = No change; 7 = Very much worse. Percentage of participants improving in CGI-C at Visit 9

    Time frame: Baseline to Visit 9 (approximately 6 months)

07

Results

Posted Apr 30, 2026

Participant flow

Participants were randomized (1:1) to eDSP or placebo group via an independent Interactive Web Response System and were stratified by age (6-9 years or ≥10 years), gender, and region (USA vs. other countries). 105 study participants were randomized and 105 received at least one study treatment.

Participant flow — Overall Study
MilestoneDexamethasone Sodium PhosphatePlacebo
Started5154
Completed4952
Not completed22

Outcome measures

PrimaryRescored Modified International Cooperative Ataxia Rating Scale (RmICARS)

Change of the RmICARS from baseline to Visit 9 compared to placebo (6 to 9 years old). RmICARS (International Cooperative Ataxia Rating Scale): Score (range 0-29); higher score indicates worse disease.

Time frame:
Baseline to Visit 9 (approximately 6 months)
Reported as:
Least squares mean · RmICARS score (0-29 points)
Rescored Modified International Cooperative Ataxia Rating Scale (RmICARS)
RmICARS score (0-29 points)Dexamethasone Sodium PhosphatePlacebo
Rescored Modified International Cooperative Ataxia Rating Scale (RmICARS)0.94 ± 4.132.24 ± 3.42
SecondaryClinical Global Impression of Severity (CGI-S)

CGI-S (Clinical Global Impression of Severity): 7-point scale; higher score indicates worse disease. 1 = Normal, not at all ill; 7 = Among the most extremely ill. Percentage of participants improving in CGI-S from baseline to Visit 9.

Time frame:
Baseline to Visit 9 (approximately 6 months)
Reported as:
Count of participants · Participants
Clinical Global Impression of Severity (CGI-S)
ParticipantsDexamethasone Sodium PhosphatePlacebo
Clinical Global Impression of Severity (CGI-S)87
SecondaryClinical Global Impression of Change (CGI-C)

CGI-C (Clinical Global Impression of Change): 7-point scale; higher score indicates worsening of disease. 1 = Very much improved; 4 = No change; 7 = Very much worse. Percentage of participants improving in CGI-C at Visit 9

Time frame:
Baseline to Visit 9 (approximately 6 months)
Reported as:
Count of participants · Participants
Clinical Global Impression of Change (CGI-C)
ParticipantsDexamethasone Sodium PhosphatePlacebo
Clinical Global Impression of Change (CGI-C)136

Adverse events

Collected over Timeframe is from baseline (or first dose, as defined) to Visit 10 (approximately 6 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dexamethasone Sodium Phosphate0/51 (0%)2/51 (3.9%)47/51 (92.2%)
Placebo0/54 (0%)3/54 (5.6%)50/54 (92.6%)
Most frequent serious events
Most frequent serious events
EventDexamethasone Sodium PhosphatePlacebo
Lower respiratory tract infectionInfections and infestations1/510/54
DiplopiaEye disorders1/510/54
BronchiectasisRespiratory, thoracic and mediastinal disorders0/511/54
DystoniaNervous system disorders0/511/54
Esophageal varices hemorrhageGastrointestinal disorders0/511/54
Most frequent other events
Showing 10 of 15
Most frequent other events
EventDexamethasone Sodium PhosphatePlacebo
PruritusSkin and subcutaneous tissue disorders14/512/54
VomitingGastrointestinal disorders11/5113/54
PyrexiaGeneral disorders12/517/54
NasopharyngitisInfections and infestations5/5111/54
CoughRespiratory, thoracic and mediastinal disorders5/519/54
HeadacheNervous system disorders8/515/54
FatigueGeneral disorders7/515/54
Upper respiratory tract infectionInfections and infestations6/514/54
NauseaGastrointestinal disorders0/516/54
Blood culture positiveInvestigations4/516/54

Baseline characteristics

The ITT population consisted of 105 participants, 51 of whom were assigned to the eDSP group and 54 in the placebo group. Efficacy endpoints were analyzed in the efficacy population, 6-9-year-olds (N=83), while the safety population included all 105 enrolled participants who received at least one dose of treatment.

Age, Categorical
Age, Categorical(Participants)Dexamethasone Sodium PhosphatePlaceboTotal
<=18 years5154105
Between 18 and 65 years000
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Dexamethasone Sodium PhosphatePlaceboTotal
Female242650
Male272855
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dexamethasone Sodium PhosphatePlaceboTotal
American Indian or Alaska Native000
Asian426
Native Hawaiian or Other Pacific Islander000
Black or African American426
White414788
More than one race000
Unknown or Not Reported235
Region of Enrollment
Region of Enrollment(Participants)Dexamethasone Sodium PhosphatePlaceboTotal
United States131528
Denmark112
Germany101222
Italy213
Norway325
Poland5914
Spain6612
Switzerland123
United Kingdom10616
Rescored modified version of the International Cooperative Ataxia Rating Scale (RmICARS)
Rescored modified version of the International Cooperative Ataxia Rating Scale (RmICARS)(rmICARS Score)Dexamethasone Sodium PhosphatePlaceboTotal
Mean9.8 ± 5.258.6 ± 5.669.2 ± 5.46
08

Study locations

19 sites
  • University of California Los Angeles (UCLA), Ataxia Center and HD Center of excellence
    Los Angeles, California 90095, United States
  • The Johns Hopkins Hospital, Division of pediatric allergy and immunology
    Baltimore, Maryland 21289, United States
  • Cincinnati Children's Hospital, Division of neurology
    Cincinnati, Ohio 45229, United States
  • UT Health Houston, Department of pediatrics, division of child & adolescent neurology
    Houston, Texas 77030, United States
  • Copenhagen University Hospital, Rigshospitalet, Department of Pediatric Neurology
    Copenhagen, 2100, Denmark
  • University Hospital Frankfurt, Pediatric and Adolescent Clinic
    Frankfurt, 60590, Germany
  • IKF Pneumologie GmbH & Co. KG; Institut für klinische Forschung Pneumologie Clinical Research Center Respiratory Diseases
    Frankfurt, 60596, Germany
  • Spedali Civili di Brescia, Pediatric immunology department
    Brescia, 25123, Italy
  • Policlinico Umberto I, La sapienza University, Department of neurosciences and menthal health
    Roma, 00161, Italy
  • Oslo University Hospital, Rikshospitalet, Division of Pediatric and Adolescent Medicine, Norwegian National Unit for Newborn Screening
    Oslo, 0372, Norway
  • MedPolonia sp zoo
    Poznan, 60-693, Poland
  • Instytut "Pomnik-Centrum Zdrowia Dziecka", Immunology clinic
    Warsaw, 04-736, Poland
  • Hospital Universitari Vall d'Hebron, Department of pediatric neurology
    Barcelona, 08035, Spain
  • Hospital Universitario La Paz, Department of pediatric neurology
    Madrid, 28046, Spain
  • University Children's Hospital Zürich - Eleonore Foundation
    Zurich, CH-8008, Switzerland
  • University Hospitals Birmingham NHS Foundation Trust
    Birmingham, B152GW, United Kingdom
  • St George's University Hospitals NHS Foundation Trust, Centre for Neonatal and Paediatric Infection
    London, SW17 0RE, United Kingdom
  • Great Ormond Street Hospital for Children, Zayed Centre for Research
    London, WC1N 1DZ, United Kingdom
  • Nottingham Children's Hospital, Queen's Medical Center, Children's neurology
    Nottingham, NG7 2UH, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2024 to primary completion in Dec 2025, 17 months.

Results were first posted in Apr 2026, 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2023
First posted
Jan 5, 2024
StartActual
Jun 24, 2024
Primary completionActual
Dec 17, 2025
CompletionActual
Dec 17, 2025
Results first posted
Apr 30, 2026
Last update
Apr 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06193200
Lead sponsor
Quince Therapeutics S.p.A.
Collaborators
Biotrial
Responsible party
Sponsor
First posted
Jan 5, 2024
Start date
Jun 24, 2024
Primary completion
Dec 17, 2025
Completion
Dec 17, 2025
Results posted
Apr 30, 2026
Last update
Apr 30, 2026

Study contacts

Dirk Thye, MD
study director · Quince Therapeutics S.p.A.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone phosphate

Start the discussion